7 Review of guidance

7.1 The guidance on this technology in people who have had previous treatment with conventional DMARDs only will be reviewed with NICE technology appraisal guidance 130 and 186. The guidance on this technology in people who have had previous treatment with both conventional DMARDs and a TNF inhibitor will be reviewed with the review of NICE technology appraisal guidance 195 in June 2013.

Andrew Dillon
Chief Executive
June 2011

  • National Institute for Health and Care Excellence (NICE)